Linked Life Data

11962679

Source:http://linkedlifedata.com/resource/pubmed/id/11962679

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2002-4-18
pubmed:abstractText
The circadian timing of surgery, anticancer drugs, radiation therapy, and biologic agents can result in improved toxicity profiles, tumor control, and host survival. Optimally timed cancer chemotherapy with doxorubicin or pirarubicin (06:00h) and cisplatin (18:00h) enhanced the control of advanced ovarian cancer while minimizing side effects, and increased the response rate in metastatic endometrial cancer. Therapy of metastatic bladder cancer with doxorubicin-cisplatin was made more tolerable by this same circadian approach resulting in a 57% objective response rate. This optimally timed therapy is also effective in the adjuvant setting, decreasing the expected frequency of metastasis from locally advanced bladder cancer. Circadian fluorodeoxyuridine (FUDR) continuous infusion (70% of the daily dose given between 15:00h and 21:00h) has been shown effective for metastatic renal cell carcinoma resulting in 29% objective response and stable disease of more than 1 yr duration in the majority of patients. Toxicity is reduced markedly when FUDR infusion is modulated to circadian rhythms. In a multicenter trial in patients with metastatic renal cell cancer, patients were randomized to a flat or a circadian-modified FUDR infusion. This study confirmed a significant difference in toxicity and dose intensity, favoring the circadian-modified group. Hormone refractory metastatic prostate cancer has been treated with circadian-timed FUDR chemotherapy; however, without objective response. Biological agents such as interferon-alpha and IL-2 have shown low but effective disease control in metastatic renal cell cancer, however, with much toxicity. Each of these cytokines shows circadian stage dependent toxicity and efficacy in model systems. In summary, the timing of anthracycline, platinum, and fluoropyrimidine-based drug therapies during the 24h is relevant to the toxic therapeutic ratio of these agents in the treatment of gynecologic and genitourinary cancers.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0742-0528
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
237-51
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:11962679-Animals, pubmed-meshheading:11962679-Antineoplastic Agents, pubmed-meshheading:11962679-Carcinoma, Renal Cell, pubmed-meshheading:11962679-Cell Cycle, pubmed-meshheading:11962679-Chronotherapy, pubmed-meshheading:11962679-Circadian Rhythm, pubmed-meshheading:11962679-Cisplatin, pubmed-meshheading:11962679-Doxorubicin, pubmed-meshheading:11962679-Endometrial Neoplasms, pubmed-meshheading:11962679-Female, pubmed-meshheading:11962679-Floxuridine, pubmed-meshheading:11962679-Genital Neoplasms, Female, pubmed-meshheading:11962679-Humans, pubmed-meshheading:11962679-Kidney Neoplasms, pubmed-meshheading:11962679-Male, pubmed-meshheading:11962679-Ovarian Neoplasms, pubmed-meshheading:11962679-Prostatic Neoplasms, pubmed-meshheading:11962679-Rats, pubmed-meshheading:11962679-Urinary Bladder Neoplasms, pubmed-meshheading:11962679-Urogenital Neoplasms
pubmed:year
2002
pubmed:articleTitle
Circadian chemotherapy for gynecological and genitourinary cancers.
pubmed:affiliation
WJB Dorn VA Medical Center/Department of Developmental Biology and Anatomy, The University of South Carolina School of Medicine, Columbia 29209, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Review, Research Support, Non-U.S. Gov't